{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:05:49Z","timestamp":1763039149764,"version":"3.45.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41569-025-01224-0","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:51:02Z","timestamp":1760359862000},"page":"921-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AQUATIC findings sink antiplatelet therapy for patients with chronic coronary syndrome requiring oral anticoagulants"],"prefix":"10.1038","volume":"22","author":[{"given":"William A. E.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints, C. et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 45, 3415\u20133537 (2024).","journal-title":"Eur. Heart J."},{"issue":"Suppl. M","key":"1224_CR2","doi-asserted-by":"publisher","first-page":"M26","DOI":"10.1093\/eurheartj\/suaa165","volume":"22","author":"WAE Parker","year":"2020","unstructured":"Parker, W. A. E. et al. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. Eur. Heart J. Suppl. 22 (Suppl. M), M26\u2013M34 (2020).","journal-title":"Eur. Heart J. Suppl."},{"key":"1224_CR3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","volume":"85","author":"S Rashedi","year":"2025","unstructured":"Rashedi, S. et al. Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials. J. Am. Coll. Cardiol. 85, 1189\u20131203 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1224_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507532","author":"G Lemesle","year":"2025","unstructured":"Lemesle, G. et al. Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2507532 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/heartjnl-2020-316914","volume":"107","author":"WAE Parker","year":"2021","unstructured":"Parker, W. A. E. & Storey, R. F. Antithrombotic therapy for patients with chronic coronary syndromes. Heart 107, 925\u2013933 (2021).","journal-title":"Heart"},{"key":"1224_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1055\/s-0038-1657768","volume":"118","author":"W Sumaya","year":"2018","unstructured":"Sumaya, W. et al. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI study). Thromb. Haemost. 118, 1250\u20131256 (2018).","journal-title":"Thromb. Haemost."},{"key":"1224_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4244\/EIJY14M09_11","volume":"11","author":"G Ducrocq","year":"2015","unstructured":"Ducrocq, G. et al. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention 11, 737\u2013745 (2015).","journal-title":"EuroIntervention"},{"key":"1224_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/heartjnl-2024-324744","volume":"111","author":"WAE Parker","year":"2025","unstructured":"Parker, W. A. E. Evolution of coronary stents: innovations, antithrombotic strategies and future directions. Heart 111, 753\u2013762 (2025).","journal-title":"Heart"},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319\u20131330 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"2507037","DOI":"10.1080\/09537104.2025.2507037","volume":"36","author":"MA Sammut","year":"2025","unstructured":"Sammut, M. A. et al. Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel. Platelets 36, 2507037 (2025).","journal-title":"Platelets"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01224-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:02:33Z","timestamp":1763038953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01224-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01224-0","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"type":"print","value":"1759-5002"},{"type":"electronic","value":"1759-5010"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"13 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.A.E.P. has received consulting fees and research support from AstraZeneca. R.F.S. has received research grants from AstraZeneca and CytoSorbents, and personal fees from Abbott, Afortiori Development\/Thrombolytic Science, AstraZeneca, Boehringer Ingelheim\/Lilly, Bristol Myers Squibb, Chiesi, Cytosorbents, Idorsia\/Viatris, Johnson & Johnson, Novo Nordisk, PhaseBio and Tabuk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}